Scientists have developed a new tuberculosis test that produces fast, accurate results in less than half an hour and does not require a phlegm sample — overcoming long-standing limitations of conventional TB diagnostics that have hampered global efforts to control one of the world's deadliest infectious diseases.
A new tuberculosis diagnostic test is being hailed as a significant breakthrough in the fight against a disease that kills more than a million people each year worldwide. Unlike conventional TB tests, which rely on phlegm samples that can be difficult to collect and process, the new test uses an alternative biological sample, delivers results in under 30 minutes, and demonstrates improved accuracy — reducing the false positives and false negatives that have long plagued existing methods.
Tuberculosis remains one of the world's most persistent public health challenges. The World Health Organization estimates that roughly 10 million people contract TB each year, with the disease disproportionately affecting low- and middle-income countries across sub-Saharan Africa, South Asia, and Southeast Asia. Despite being preventable and treatable, TB continues to spread in part because of the difficulties associated with timely and reliable diagnosis.
Current standard diagnostic methods — including sputum smear microscopy and culture-based tests — require patients to produce phlegm, a task that is particularly difficult for children, elderly patients, and those with early-stage or extrapulmonary TB. Culture-based tests, while more accurate, can take weeks to return results. Rapid molecular tests such as GeneXpert have improved the situation in recent years, but still depend on sputum samples and require cold-chain logistics and technical infrastructure that many rural health facilities lack.
The new test addresses several of these barriers simultaneously. By removing the need for phlegm, it opens the door to diagnosis for patient groups previously underserved by existing tools. Its speed — results in less than 30 minutes — means clinicians could potentially diagnose and begin treating patients in a single visit, reducing the risk that patients are lost to follow-up before treatment begins. Improved accuracy, meanwhile, could prevent the unnecessary treatment of healthy patients and ensure those who are sick receive timely care.
Global health experts have long called for a point-of-care TB test that is fast, accurate, and easy to use in low-resource settings. Whether this new test can meet that bar at scale — in terms of cost, manufacturing, and deployment — will be a key question as it moves toward wider evaluation and potential regulatory approval.
The development comes at a critical moment. Drug-resistant TB strains are on the rise globally, making rapid and accurate diagnosis even more important. Identifying TB quickly allows clinicians to tailor treatment regimens and helps prevent the further spread of resistant strains.
Analysis
Why This Matters
- Tuberculosis kills over 1 million people annually, and late or missed diagnoses are a major driver of transmission — a faster, more accessible test could meaningfully reduce that toll.
- Removing the phlegm requirement is particularly significant for children and patients with extrapulmonary TB, groups who are chronically underdiagnosed with existing tools.
- If the test proves scalable and affordable, it could shift TB care toward single-visit diagnosis-and-treatment models in resource-limited settings, a long-sought goal in global health.
Background
Tuberculosis has shadowed humanity for millennia and remains one of the leading infectious disease killers globally, despite the existence of effective treatments. For most of the 20th century, TB diagnosis relied on sputum smear microscopy — a method requiring phlegm, laboratory infrastructure, and trained technicians, with sensitivity as low as 50–60% in some settings.
The introduction of GeneXpert (Xpert MTB/RIF) in the 2010s was a landmark moment, offering molecular-level accuracy in roughly two hours. However, it still requires sputum, electricity, and a supply chain for cartridges, limiting its reach in the most remote areas. The WHO has for years listed a rapid, non-sputum-based point-of-care test as a top global health research priority.
The rise of drug-resistant TB — particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains — has further raised the stakes for accurate, timely diagnosis, since patients started on the wrong drug regimen can deteriorate rapidly and spread resistant strains to others.
Key Perspectives
Global health researchers and advocates: Have long championed the development of exactly this type of test, arguing that simpler, faster diagnostics are essential to closing the gap between TB incidence and treatment rates, particularly in high-burden countries.
Healthcare providers in low-resource settings: Stand to benefit significantly if the test can be deployed without sophisticated laboratory infrastructure, but will need assurance about cost, shelf life, and ease of use before widespread adoption is feasible.
Critics/Skeptics: Will want to see peer-reviewed clinical trial data across diverse populations and settings before drawing firm conclusions. Key questions remain about sensitivity and specificity compared to gold-standard culture methods, manufacturing scalability, and affordability for health systems in the countries that need it most.
What to Watch
- Publication of full peer-reviewed clinical trial data, including performance metrics (sensitivity, specificity) across different patient populations and TB burden settings.
- Whether WHO or national regulatory bodies fast-track review and prequalification of the test for use in high-burden countries.
- Pricing and licensing negotiations between the test's developers and global health procurement bodies such as the Global Fund and UNITAID, which will determine whether the test reaches those who need it most.